Delivery Order SPE2DB24D2018-SPE2DB25FWWJ0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $14,991.13. This non-set-aside delivery order was competitively awarded and is set to complete by August 6, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60-count unit) valued at $1,926.04. This firm fixed-price contract, which reaches completion on August 6, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The delivery order carries no set-aside...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,266.36 by the Defense Logistics Agency (DLA) on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract, which is not set-aside and competitively awarded, calls for the delivery of Ibsrela 50 mg tablets in quantities of 60 units. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) with a ceiling value of $10,513.99. This firm fixed-price delivery order, which is not set-aside for small business or other designated groups, is scheduled for completion by August 1, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,691.58 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies totaling $3,425.94, with completion scheduled for August 18, 2025. This non-set-aside, competitively awarded contract covers the supply of Ibsrela 50 mg tablets (60-count units) to be delivered to the contractor's facility in Conshohocken, Pennsylvania. The award employs firm fixed pricing under a delivery order contract type, reflecting the standardized procurement approach...
- The Defense Logistics Agency awarded a delivery order valued at $13,445.69 to AmerisourceBergen Drug Corp for IBSRELA 50 mg tablets (60-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was awarded on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $10,409.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for IBSRELA 50 mg tablets (60-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order was performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement supporting federal medical supply needs. The award is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,898.52 to AmerisourceBergen Drug Corp for IBSRELA 50 MG tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $3,477.01 to AmerisourceBergen Drug Corp for IBSRELA 50 mg tablets (60-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWJ0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $21,030.84, with completion expected by August 21, 2025. This competitively awarded, non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Department of Defense medical supply chain and holds a substantial Indefinite Delivery Contract (valued at $999,999,999.00) with DLA Troop Support Medical through December 2026, enabling the company to supply a comprehensive range of medications and medical commodities to military healthcare systems worldwide. This delivery order falls under AmerisourceBergen's larger pharmaceutical prime vendor contract with the Defense Logistics Agency, which facilitates the distribution of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains in support of military health programs. The company's extensive federal contract portfolio demonstrates its established capability to fulfill competitive procurement requirements and deliver diverse pharmaceutical products to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems on an expedited basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.0k | 8/20/25 |